Patheon N.V. (NYSE:PTHN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
release announcing preliminary unaudited financial results for
its fiscal quarter ended January 31, 2017. The full text of the
press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K (this Report) and incorporated by reference into this
information in Item 2.02 of this Report, including the press
release attached as Exhibit 99.1, is furnished and shall not be
deemed to be filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section. Furthermore, such information shall
not be deemed to be incorporated by reference into the filings of
the registrant under the Securities Act of 1933, as amended.
Press Release, dated March 16, 2017.
About Patheon N.V. (NYSE:PTHN)
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing. Patheon N.V. (NYSE:PTHN) Recent Trading Information
Patheon N.V. (NYSE:PTHN) closed its last trading session up +0.48 at 31.39 with 641,216 shares trading hands.